Cargando…
Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)F] fluorodeoxyglucose and [(18)F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging
PURPOSE: To compare [(18)F]-fluorodeoxyglucose (FDG) and [(18)F]-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) with whole-body magnetic resonance with diffusion-weighted imaging (WB-MRI), for endocrine therapy response prediction at 8 weeks in bone-predominant metas...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450846/ https://www.ncbi.nlm.nih.gov/pubmed/30506455 http://dx.doi.org/10.1007/s00259-018-4223-9 |
_version_ | 1783409078040526848 |
---|---|
author | Azad, Gurdip K. Taylor, Benjamin P. Green, Adrian Sandri, Ines Swampillai, Angela Harries, Mark Kristeleit, Hartmut Mansi, Janine Goh, Vicky Cook, Gary J. R. |
author_facet | Azad, Gurdip K. Taylor, Benjamin P. Green, Adrian Sandri, Ines Swampillai, Angela Harries, Mark Kristeleit, Hartmut Mansi, Janine Goh, Vicky Cook, Gary J. R. |
author_sort | Azad, Gurdip K. |
collection | PubMed |
description | PURPOSE: To compare [(18)F]-fluorodeoxyglucose (FDG) and [(18)F]-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) with whole-body magnetic resonance with diffusion-weighted imaging (WB-MRI), for endocrine therapy response prediction at 8 weeks in bone-predominant metastatic breast cancer. PATIENTS AND METHODS: Thirty-one patients scheduled for endocrine therapy had up to five bone metastases measured [FDG, NaF PET/CT: maximum standardized uptake value (SUV(max)); WB-MRI: median apparent diffusion coefficient (ADC(med))] at baseline and 8 weeks. To detect the flare phenomenon, a 12-week NaF PET/CT was also performed if 8-week SUV(max) increased. A 25% parameter change differentiated imaging progressive disease (PD) from non-PD and was compared to a 24-week clinical reference standard and progression-free survival (PFS). RESULTS: Twenty-two patients (median age, 58.6 years, range, 40–79 years) completing baseline and 8-week imaging were included in the final analysis. Per-patient % change in NaF SUV(max) predicted 24-week clinical PD with sensitivity, specificity and accuracy of 60, 73.3, and 70%, respectively. For FDG SUV(max) the results were 0, 100, and 76.2% and for ADC(med), 0, 100 and 72.2%, respectively. PFS < 24 weeks was associated with % change in SUV(max) (NaF: 41.7 vs. 0.7%, p = 0.039; FDG: − 4.8 vs. − 28.6%, p = 0.005) but not ADC(med) (− 0.5 vs. 10.1%, p = 0.098). Interlesional response heterogeneity occurred in all modalities and NaF flare occurred in seven patients. CONCLUSIONS: FDG PET/CT and WB-MRI best predicted clinical non-PD and both FDG and NaF PET/CT predicted PFS < 24 weeks. Lesional response heterogeneity occurs with all modalities and flare is common with NaF PET/CT. |
format | Online Article Text |
id | pubmed-6450846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-64508462019-04-17 Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)F] fluorodeoxyglucose and [(18)F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging Azad, Gurdip K. Taylor, Benjamin P. Green, Adrian Sandri, Ines Swampillai, Angela Harries, Mark Kristeleit, Hartmut Mansi, Janine Goh, Vicky Cook, Gary J. R. Eur J Nucl Med Mol Imaging Original Article PURPOSE: To compare [(18)F]-fluorodeoxyglucose (FDG) and [(18)F]-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) with whole-body magnetic resonance with diffusion-weighted imaging (WB-MRI), for endocrine therapy response prediction at 8 weeks in bone-predominant metastatic breast cancer. PATIENTS AND METHODS: Thirty-one patients scheduled for endocrine therapy had up to five bone metastases measured [FDG, NaF PET/CT: maximum standardized uptake value (SUV(max)); WB-MRI: median apparent diffusion coefficient (ADC(med))] at baseline and 8 weeks. To detect the flare phenomenon, a 12-week NaF PET/CT was also performed if 8-week SUV(max) increased. A 25% parameter change differentiated imaging progressive disease (PD) from non-PD and was compared to a 24-week clinical reference standard and progression-free survival (PFS). RESULTS: Twenty-two patients (median age, 58.6 years, range, 40–79 years) completing baseline and 8-week imaging were included in the final analysis. Per-patient % change in NaF SUV(max) predicted 24-week clinical PD with sensitivity, specificity and accuracy of 60, 73.3, and 70%, respectively. For FDG SUV(max) the results were 0, 100, and 76.2% and for ADC(med), 0, 100 and 72.2%, respectively. PFS < 24 weeks was associated with % change in SUV(max) (NaF: 41.7 vs. 0.7%, p = 0.039; FDG: − 4.8 vs. − 28.6%, p = 0.005) but not ADC(med) (− 0.5 vs. 10.1%, p = 0.098). Interlesional response heterogeneity occurred in all modalities and NaF flare occurred in seven patients. CONCLUSIONS: FDG PET/CT and WB-MRI best predicted clinical non-PD and both FDG and NaF PET/CT predicted PFS < 24 weeks. Lesional response heterogeneity occurs with all modalities and flare is common with NaF PET/CT. Springer Berlin Heidelberg 2018-12-01 2019 /pmc/articles/PMC6450846/ /pubmed/30506455 http://dx.doi.org/10.1007/s00259-018-4223-9 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Azad, Gurdip K. Taylor, Benjamin P. Green, Adrian Sandri, Ines Swampillai, Angela Harries, Mark Kristeleit, Hartmut Mansi, Janine Goh, Vicky Cook, Gary J. R. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)F] fluorodeoxyglucose and [(18)F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging |
title | Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)F] fluorodeoxyglucose and [(18)F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging |
title_full | Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)F] fluorodeoxyglucose and [(18)F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging |
title_fullStr | Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)F] fluorodeoxyglucose and [(18)F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging |
title_full_unstemmed | Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)F] fluorodeoxyglucose and [(18)F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging |
title_short | Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)F] fluorodeoxyglucose and [(18)F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging |
title_sort | prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)f] fluorodeoxyglucose and [(18)f]-fluoride pet/ct with whole-body mri with diffusion-weighted imaging |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450846/ https://www.ncbi.nlm.nih.gov/pubmed/30506455 http://dx.doi.org/10.1007/s00259-018-4223-9 |
work_keys_str_mv | AT azadgurdipk predictionoftherapyresponseinbonepredominantmetastaticbreastcancercomparisonof18ffluorodeoxyglucoseand18ffluoridepetctwithwholebodymriwithdiffusionweightedimaging AT taylorbenjaminp predictionoftherapyresponseinbonepredominantmetastaticbreastcancercomparisonof18ffluorodeoxyglucoseand18ffluoridepetctwithwholebodymriwithdiffusionweightedimaging AT greenadrian predictionoftherapyresponseinbonepredominantmetastaticbreastcancercomparisonof18ffluorodeoxyglucoseand18ffluoridepetctwithwholebodymriwithdiffusionweightedimaging AT sandriines predictionoftherapyresponseinbonepredominantmetastaticbreastcancercomparisonof18ffluorodeoxyglucoseand18ffluoridepetctwithwholebodymriwithdiffusionweightedimaging AT swampillaiangela predictionoftherapyresponseinbonepredominantmetastaticbreastcancercomparisonof18ffluorodeoxyglucoseand18ffluoridepetctwithwholebodymriwithdiffusionweightedimaging AT harriesmark predictionoftherapyresponseinbonepredominantmetastaticbreastcancercomparisonof18ffluorodeoxyglucoseand18ffluoridepetctwithwholebodymriwithdiffusionweightedimaging AT kristeleithartmut predictionoftherapyresponseinbonepredominantmetastaticbreastcancercomparisonof18ffluorodeoxyglucoseand18ffluoridepetctwithwholebodymriwithdiffusionweightedimaging AT mansijanine predictionoftherapyresponseinbonepredominantmetastaticbreastcancercomparisonof18ffluorodeoxyglucoseand18ffluoridepetctwithwholebodymriwithdiffusionweightedimaging AT gohvicky predictionoftherapyresponseinbonepredominantmetastaticbreastcancercomparisonof18ffluorodeoxyglucoseand18ffluoridepetctwithwholebodymriwithdiffusionweightedimaging AT cookgaryjr predictionoftherapyresponseinbonepredominantmetastaticbreastcancercomparisonof18ffluorodeoxyglucoseand18ffluoridepetctwithwholebodymriwithdiffusionweightedimaging |